Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function

David M. Barrett, MD PhD, Nathan Singh, MD, Ted J. Hofmann, PhD, Zachary Gershenson, Stephan A. Grupp, MD PhD

Blood (2016) 128 (22): 654.

https://doi.org/10.1182/blood.V128.22.654.654

Published: 2016

Journal Articles

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Saba Ghassemi, PhD, Patel Prachi, John Scholler, Selene Nunez-Cruz, PhD, David M. Barrett, MD PhD, Felipe Bedoya, PhD, Joseph A. Fraietta, PhD, Simon Francis Lacey, PhD BS, Bruce L Levine, PhD, Stephen A. Grupp, MD PhD, Carl H June, MD, Michael C. Milone, MD PhD, J. Joseph Melenhorst, PhD

Blood (2016) 128 (22): 4549.

https://doi.org/10.1182/blood.V128.22.4549.4549

Published: 2016

Journal Articles

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 217.

https://doi.org/10.1182/blood.V128.22.217.217

Published: 2016

Journal Articles

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR

Blood (2016) 128 (22): 281.

https://doi.org/10.1182/blood.V128.22.281.281

Published: 2016

Journal Articles

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Pamela A Shaw, PhD, Richard Aplenc, MD PhD, David M. Barrett, MD PhD, Colleen Callahan, MSN, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, J Joseph Melenhorst, PhD, Laura Motley, RN, Susan R. Rheingold, MD, David T Teachey, MD, Patricia A. Wood, MD PhD, David Porter, MD, Carl H. June, MD

Blood (2015) 126 (23): 681.

https://doi.org/10.1182/blood.V126.23.681.681

Published: 2015

Journal Articles

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Blood (2015) 126 (23): 683.

https://doi.org/10.1182/blood.V126.23.683.683

Published: 2015

Journal Articles

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

David T Teachey, MD, Simon F. Lacey, PhD BSc, Pamela A Shaw, PhD, J Joseph Melenhorst, PhD, Noelle V. Frey, MD, Shannon L Maude, MD PhD, David M. Barrett, MD PhD, Richard Aplenc, MD PhD, Fang Chen, PhD, Julie Fitzgerald, MD PhD, Vanessa Gonzalez, M.B.A, Edward Pequignot, PhD, Susan R. Rheingold, MD, Scott Weiss, MD, Jason C. White, DO, Carl H. June, MD, David L. Porter, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 1334.

https://doi.org/10.1182/blood.V126.23.1334.1334

Published: 2015

Journal Articles

Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David M. Barrett, MD PhD, Saad S Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, J. Joseph Melenhorst, PhD, Farzana Nazimuddin, Jessica Perazzelli, PhD, David A Christian, PhD, Christopher A Hunter, PhD, David L Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I Gill, MBBS, PhD

Blood (2015) 126 (23): 2523.

https://doi.org/10.1182/blood.V126.23.2523.2523

Published: 2015

Journal Articles

Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites

Xiaojun Liu, Master, David M. Barrett, MD PhD, Shuguang Jiang, PhD, Chongyun Fang, PhD, Stephan A. Grupp, MD PhD, Carl H. June, MD, Yangbing Zhao, PhD MD

Blood (2015) 126 (23): 4431.

https://doi.org/10.1182/blood.V126.23.4431.4431

Published: 2015

Journal Articles

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Susan R. Rheingold, MD, Lanyi Nora Chen, BS, Shannon L Maude, MD PhD, Richard Aplenc, MD PhD, Christine Barker, BS, David M. Barrett, MD PhD, Colleen Callahan, MSN, Katherine Cebry, Irina Kulikovskaya, PhD, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, Jan J. Melenhorst, PhD, Pamela A Shaw, PhD, Anna Sparrow, David T Teachey, MD, Mark Duckworth, BS, Carl H. June, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 3769.

https://doi.org/10.1182/blood.V126.23.3769.3769

Published: 2015

Journal Articles

Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr

Haying Qin, Cho Monica, Waleed Haso, M.S., Ling Zhang, David M. Barrett, MD/PhD, Rimas J Orentas, PhD, Stephan A. Grupp, MD, PhD, Terry J Fry, MD

Blood (2013) 122 (21): 2665.

https://doi.org/10.1182/blood.V122.21.2665.2665

Published: 2013

Journal Articles

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Stephan A Grupp, MD, PhD, Noelle V. Frey, MD, Richard Aplenc, MD, PhD, David M Barrett, MD/PhD, Anne Chew, PhD, Michael Kalos, PhD, Bruce L. Levine, PhD, Manuel Litchman, MD, Shannon L Maude, MD, PhD, Susan R. Rheingold, Angela Shen, MD, Christine Strait, David T. Teachey, MD, Patricia A. Wood, MD, PhD, David Porter, MD, Carl H. June, MD

Blood (2013) 122 (21): 67.

https://doi.org/10.1182/blood.V122.21.67.67

Published: 2013

Journal Articles

A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia

Alix E. Seif, MD, MPH, David M. Barrett, MD/PhD, Stephan A. Grupp, MD, PhD, Gregor S.D. Reid, PhD

Blood (2012) 120 (21): 3540.

https://doi.org/10.1182/blood.V120.21.3540.3540

Published: 2012

Journal Articles

CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).

Stephan A. Grupp, MD, PhD, David L Porter, MD, David T Teachey, MD, David M. Barrett, MD/PhD, Anne Chew, PhD, Erica Suppa, Bruce L. Levine, PhD, Michael Kalos, PhD, Carl H. June, MD

Blood (2012) 120 (21): 2604.

https://doi.org/10.1182/blood.V120.21.2604.2604

Published: 2012

Journal Articles

Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia

David M Barrett, MD/PhD, Alix E Seif, MD, Carmine Carpenito, PhD, Eliza P Strong, Carl H. June, MD, Stephan A. Grupp, MD, PhD, Gregor S. D. Reid, PhD

Blood (2010) 116 (21): 2140.

https://doi.org/10.1182/blood.V116.21.2140.2140

Published: 2010

NARROW

Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies

Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia

CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).

Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only